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Abstract: Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20. 
Since its first approval for clinical use in 1997, rituximab has become an inherent part of the 
treatment of CD20-positive lymphoma. In previously untreated non-Hodgkin lymphoma (NHL) 
conventional chemotherapy supplemented by rituximab (R-chemotherapy) was shown to be 
more effective than chemotherapy alone. This holds true for indolent as well as aggressive 
NHL. Rituximab was also shown to be beneficial when used as maintenance therapy or part of 
salvage and re-induction regimens in relapsed NHL. Administration of rituximab is generally 
well tolerated. The most common side effects including fever, urticaria and bronchospasm are 
mostly mild, treatable and restricted to the infusion period. Thus, rituximab can usually be 
administered in an outpatient setting. Due to its favorable effect/side effect ratio, clinical trials 
are currently evaluating a possible role for rituximab in several other diseases such as Hodgkin 
lymphoma (HL) and non-malignant autoimmune disorders. This review aims at giving an 
overview of the pharmacological properties of rituximab and summarizing key publications 
and recent literature on its use in NHL.
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Introduction
Non-Hodgkin lymphoma (NHL) has been classified into two types: aggressive (ie, fast 
growing) and indolent (ie, slow growing).1 Aggressive NHL such as the most common 
NHL subtype diffuse large B cell lymphoma (DLBCL) are characterized by a rapid 
tumor growth resulting in death of patients after a few weeks to months if untreated. 
Thus, treatment must be initiated immediately after diagnosis. However, patients with 
aggressive NHL can potentially be cured with an appropriate multi-agent chemotherapy.2 
In contrast, indolent NHL such as follicular lymphoma (FL) are mostly incurable and 
patients are commonly in a palliative situation. Here, only a small portion of patients 
diagnosed at an early stage achieve long-term disease-free survival by radiotherapy and 
can be considered cured.3 In the vast majority of patients with indolent NHL, disease 
is diagnosed at an advanced stage. In these patients treatment is not indicated until 
disease becomes symptomatic since no survival benefit for patients undergoing early 
treatment compared to patients pursuing a watch-and-wait strategy has been shown 
to date.4 When disease becomes symptomatic and treatment is applied, patients with 
indolent NHL usually show good response to first-line therapy. Unfortunately, there 
are only few long-term survivors. The median survival is 8 to 10 years.5
In the past decade treatment of NHL and particularly of B cell NHL, which 
represents 85% to 90% of all NHL cases, has improved significantly,6 mainly because OncoTargets and Therapy 2009:2 190
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of the advent of antibody-based immunotherapy and its 
implementation in NHL treatment protocols.
The immunotherapeutic agent most widely used is the 
anti-CD20 antibody rituximab. Since its first approval for 
clinical use in 1997, indications for rituximab in lymphoma 
treatment expanded fundamentally so that current B cell 
lymphoma therapy is inconceivable without rituximab.
Rituximab
Rituximab is a chimeric monoclonal antibody directed 
against the surface antigen CD20. CD20 is expressed on 
nearly all malignant and mature B cells but, importantly, not 
on plasma cells, precursor B cells and stem cells.7 Rituximab 
is composed of murine variable regions linked to a human Fc 
component.8 Various effects such as complement-dependent 
lysis, effector cell-mediated lysis, induction of apoptosis, 
direct growth arrest and sensitization to conventional chemo-
therapy were observed upon CD20 binding of rituximab and 
contribute to the antibody’s activity.8–10
Since CD20 is not internalized or shed from the cell surface 
and does not circulate in the plasma, anti-CD20 antibody-
based immunotherapy was soon regarded as a promising 
tool in the treatment of B cell NHL, and consequently the 
first clinical trials evaluating safety and efficacy of rituximab 
were started in the early 1990s.7,11 These trials resulted in the 
antibody’s approval for the treatment of relapsed and refrac-
tory low-grade or follicular CD20-positive NHL in 1997.12–14 
Since then the number of indications for the use of rituximab 
has risen steadily, and now rituximab is an essential part in 
the treatment of patients with CD20-positive NHL.
When used as single agent, rituximab is commonly admin-
istered at the standard dose of 375 mg/m2 iv once weekly for 
four doses. However, the optimal dose has never been defined 
precisely in clinical trials. The dose of 375 mg/m2 adminis-
tered weekly was chosen as standard for further testing on 
the basis of pharmacokinetic and pharmacodynamic data. In 
addition, this dose could be given safely and effectively in an 
outpatient setting.14 Serum analyses showed a median serum 
half-life for rituximab of  76.3 hours after the first infusion 
and 205.8 hours after the fourth infusion. This increase in 
serum half-life is mainly due to a decrease of the rituximab 
clearance from the first to the fourth infusion.15 Depletion of 
B cells was shown to occur within the first three doses and to 
persist for about 6 to 9 months. B cell count was found to be 
recovered about 12 months after completion of treatment.13
Despite the high activity of rituximab, novel anti-CD20 
antibodies such as the fully human antibody ofatumumab 
and the humanized antibody veltuzumab (hA20) were 
developed with the purpose of further improving anti-CD20 
immunotherapy.16,17 These antibodies might have a higher 
efficacy than rituximab due to improved pharmacological and 
binding properties and less side effects based on a reduced 
immunogenicity. They are being evaluated in phase I/II 
clinical trials and first data were recently published.18
Clinical trials with rituximab 
in indolent and mantle cell lymphoma
Based on the results of phase I/II clinical trials conducted in 
the early 1990s, rituximab was approved for clinical use in 
lymphoma therapy in 1997. Two publications in particular12,13 
played a pivotal role and paved the way for the extensive 
clinical use of rituximab.
First, a phase I dose-escalation trial mainly including 
patients with relapsed indolent lymphoma was carried out. 
Patients were treated with four weekly infusions of rituximab 
at a dosage of 125, 250 or 375 mg/m2.12 Since no dose-limiting 
toxicities were observed and pharmacokinetic and pharma-
codynamic data were considered optimal at 375 mg/m2, this 
dose was selected for further testing of single-agent activity 
in a phase II trial. In this phase II trial, 37 low-grade or FL 
patients with one to five prior lines of treatment received 
4-weekly infusions of rituximab at 375 mg/m2. Remissions 
were observed in 50% (17 patients) of evaluable patients with 
9% (3 patients) achieving complete remission (CR) and 41% 
(14 patients) achieving partial remission (PR). An additional 
8 patients (24%) showed a tumor reduction of more than 20% 
but did not qualify as responders. Median time to progres-
sion was 10.2 months. Among the patients included, those 
with follicular small cleaved histology had the best response 
rate, with 13 of 21 achieving either CR or PR. Side effects 
of therapy were mostly mild, only 6 patients experiencing 
grade III or IV adverse events. The adverse events most 
commonly observed were fever, chills and nausea.13 After this 
trial had proven the single-agent activity of rituximab even 
in relapsed and heavily pre-treated low-grade NHL patients, 
several groups started evaluating combinations of rituximab 
and conventional chemotherapy in NHL patients.
For years the cyclophosphamide/doxorubicin/vincristine/
prednisone (CHOP) scheme was considered standard first-line 
treatment for the majority of NHL entities. After single-agent 
activity of rituximab had been demonstrated, the need became 
obvious to evaluate whether a combination of CHOP and ritux-
imab might improve the results achieved with CHOP alone. 
After phase II trials had shown safety, feasibility and activity 
of rituximab-CHOP (R-CHOP), the German Low-Grade 
Lymphoma Study Group (GLSG) conducted a randomized trial OncoTargets and Therapy 2009:2 191
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including 428 previously untreated FL patients in advanced 
stages.19 Patients either received 6 to eight 8 of CHOP alone 
or 6 to 8 cycles of R-CHOP. Results showed a significant 
superiority for the combination. Overall response rate (ORR) 
was 96% in the R-CHOP arm compared to 90% in the CHOP 
arm (p = 0.011). CR was observed in 17% and 20%, and PR 
in 73% and 77% of patients treated with CHOP and R-CHOP, 
respectively. Addition of rituximab also prolonged duration 
of remission. With a median follow-up of 18 months, only 28 
of  233 patients in the R-CHOP arm experienced treatment 
failure compared to 61 of 205 patients in the CHOP arm 
(p  0.001). Median overall survival (OS) was not reached 
in both groups. However, at 3 years there were 6 deaths in 
the R-CHOP and 17 deaths in the CHOP group (p = 0.016), 
which also indicates the superiority of  the rituximab-containing 
therapy. Since the number of adverse events was comparable 
in both treatment arms, a significant superiority of R-CHOP 
over CHOP alone was the major result of this trial.20
Other clinical studies also showed the combination 
of rituximab with conventional chemotherapy to be more 
effective than chemotherapy alone. Salles et al compared 
96 patients receiving 12 cycles of the cyclophosphamide/
adriamycin/etoposide/prednisolone (CHVP) plus interferon-
alpha over 18 months with 89 patients receiving 6 cycles of 
the same chemotherapy combined with 6 applications of 
the standard dose of rituximab and interferon-alpha over 
18 months. All patients had advanced-stage FL and a 
high tumor burden. With a median follow-up of 5 years, 
patients receiving the rituximab-containing therapy had a 
significantly superior outcome. Event-free survival (EFS) 
estimates were 37% in the standard arm without rituximab 
and 53% in the rituximab-containing arm (p = 0.001). OS did 
not differ significantly between treatment arms. Here, only a 
trend towards better OS in patients receiving the rituximab 
combination was detectable.21
Another randomized phase III study comparing 162 patients 
with advanced FL treated with cyclophosphamide/vincristine/
prednisone (CVP) alone with 159 patients treated with R-CVP 
also showed superior results for the rituximab combination. 
Patients randomized into the rituximab-containing arm had 
an improved outcome for all tested endpoints. ORR were 
57% and 81% with CR rates of 10% and 41% in the CVP 
and the R-CVP arm, respectively (p  0.0001). Time to 
treatment failure (TTF) and time to progression (TTP) were 
significantly longer in the patient group treated with R-CVP 
(p  0.0001). With a median follow-up of 53 months, OS 
was also significantly superior in the R-CVP than the CVP 
arm (83% vs 77%, p = 0.029).22
Results of these trials were confirmed by a meta-analysis 
performed by the Cochrane Haematological Malignancies 
Group (CHMG). Data from 1943 patients from 7 random-
ized trials (5 including untreated and 2 including relapsed 
or refractory patients) comparing R-chemotherapy with 
chemotherapy alone in patients with FL, mantle cell lym-
phoma (MCL) and other indolent lymphoma were analyzed. 
R-chemotherapy was shown to lead to superior OS, response 
rates and disease control in comparison with chemotherapy 
alone. This held particularly true for the subgroups FL and 
MCL (Figures 1 and 2).23
To challenge the standard regimen for many indolent 
NHL, R-CHOP, the Study Group Indolent Lymphomas (StiL) 
conducted a randomized phase III trial with 439 patients 
Study  R-chemo  Chemotherapy HR  Weight   HR (95% CI)
 n/N  n/N  95% CI  %
 Forstpointner 200446        16/66  10.91     0.42 [0.23, 0.74] 
 Herold 200448,49        37/181 20.89     0.60 [0.40, 0.92] 
 Hiddemann 200520         6/223 20.85     0.60 [0.40, 0.92] 
 Lenz 200529        10/62   4.98     0.96 [0.41, 2.26] 
 Marcus 200529        21/162 11.63     0.70 [0.40, 1.23] 
 Rivas-Vera 200551        10/66  2.97     0.96 [0.32, 2.91] 
 van Oers 200626        52/234
30/62 
51/177 
17/205 
11/60 
28/159 
6/55 
65/231   27.77     0.74 [0.52, 1.07] 
Total (95% CI) 994 100.00 0.65 [0.54, 0.78]
Total events:                        152
Test for heterogeneity: Chi² = 4.42, df = 6 (p = 0.62), I² = 0%
Test for overall effect: Z = 4.45 (p < 0.00001)
 0.1  0.2  0.5  1  2  5  10
 Favors R-chemo  Favors chemotherapy
949
208 
Figure 1 Overall survival for all patients with indolent or mantle cell lymphoma who received rituximab with chemotherapy (r-chemo) or chemotherapy alone. reproduced 
with permission from Schulz H, Bohlius JF,   Trelle S, et al. immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: 
a systematic review and meta-analysis.  J Natl Cancer Inst. 2007;99(9):706–714.44 Copyright © 2007 Oxford University Press.OncoTargets and Therapy 2009:2 192
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in which R-CHOP was compared with bendamustine and 
rituximab (BR). Previous phase II trials had shown BR 
to have promising activity in indolent NHL.24 An interim 
analysis presented in 2007 revealed similar ORR and CR 
rates in the R-CHOP and the BR arm (94% vs 93% and 40% 
vs 51%, respectively). Number of deaths and the proportion 
of patients with progressive or relapsed disease were also 
comparable in both arms. Differences could be observed in 
terms of toxicity. Here, BR showed a more favorable profile, 
only 12% of patients developing grade III/IV leukocytopenia 
compared with 41% in the R-CHOP arm. Consequently, 
infectious complications were observed less frequently in 
the BR arm.25 Although final conclusions cannot be drawn 
yet because follow-up is still too short, results are promising 
and BR might challenge R-CHOP as a standard regimen for 
patients with indolent lymphoma in the coming years.
Currently, ongoing trials aim to further optimize first-line 
treatment of patients with advanced indolent lymphoma, for 
example by evaluating the role of high-dose chemotherapy 
after rituximab-containing induction therapy. In patients 
with early-stage FL who are usually treated by radiation 
only, a trial conducted by the GLSG aims at improving 
outcome of patients by administration of four weekly doses 
of rituximab as induction therapy prior to involved-field 
radiotherapy (IF-RT).
Rituximab-containing salvage regimens as well as 
rituximab maintenance therapy could also be shown to improve 
outcome of patients. Van Oers and colleagues conducted a 
trial including 465 patients with refractory or relapsed FL. 
Patients were randomized twice. The first randomization 
assigned patients to either an induction therapy with R-CHOP 
or with CHOP alone. Those patients who achieved PR or better 
were then randomized to either maintenance with rituximab 
every 3 months for a maximum of 2 years or observation. 
Rituximab-containing induction therapy as well as rituximab 
maintenance led to a superior outcome than conventional 
induction chemotherapy and observation, respectively.
After completion of induction therapy, 334 patients were 
eligible for randomization between rituximab maintenance 
and observation. With a median follow-up of 33.3 months 
from this second randomization, patients receiving rituximab 
maintenance had a median PFS of 51.5 months which was 
significantly longer than the median PFS of 14.9 months 
achieved in the observation group (p  0.001). OS was also 
significantly improved in the group receiving rituximab 
maintenance, with a 3-year OS rate of 85.1% compared 
with 77.1% in the observation group (p = 0.011).26 Similar 
results were reported by other groups. The GLSG randomly 
assigned relapsed and refractory FL and MCL patients 
to either fludarabine/cyclophosphamide/mitoxantrone 
Figure 2 Overall survival for the subgroups of patients with indolent or mantle cell lymphoma who received rituximab with chemotherapy (r-chemo) or chemotherapy 
alone.  reproduced with permission from Schulz H, Bohlius JF,   Trelle S, et al. immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell 
lymphoma: a systematic review and meta-analysis.  J Natl Cancer Inst. 2007;99(9):706–714.44 Copyright © 2007 Oxford University Press.
Study  R-chemo  Chemotherapy HR  Weight  HR (95%CI)
or sub-category  n/N  n/N  95% CI  %
Follicular lymphoma
 Forstpointner 200446         4/35  3.24     0.38 [0.12, 1.18] 
 Herold 200448,49        14/105 10.31     0.45 [0.24, 0.85] 
 Hiddemann 200520         6/223 23.89     0.60 [0.40, 0.92] 
 Marcus 200529       21/162 13.33     0.70 [0.40, 1.23] 
 van Oers 200626        52/234 31.82     0.74 [0.52, 1.07] 
Subtotal (95% CI) 759
8/30 
24/96 
17/205 
28/159 
65/231 
721 82.59      0.63 [0.51, 0.79]
Total events:                                97
Test for heterogeneity: Chi² = 2.83, df = 4 (P = 0.59), I² = 0%
Test for overall effect: Z = 3.97 (P < 0.0001)
Mantlecell lymphoma
 Forstpointner 200446         8/24  3.26     0.19 [0.06, 0.59] 
 Herold 200448,49        14/44   8.43     0.68 [0.34, 1.37] 
 Lenz 200529        10/62   5.71     0.96 [0.41, 2.26] 
Subtotal (95% CI) 130
18/24 
17/46 
11/60 
130 17.41     0.60 [0.37, 0.98]
Total events:                                32
Test for heterogeneity: Chi² = 5.21, df = 2 (p = 0.07), I² = 61.6%
Test for overall effect: Z = 2.04 (p = 0.04)
 0.1  0.2  0.5  1  2  5  10
 Favors R-chemo  Favors chemotherapy
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(FCM) or R-FCM. In addition, one group receiving ritux-
imab maintenance and one group no further treatment. With 
a median observation time of 26 months, response duration 
in patients receiving rituximab maintenance was significantly 
longer, with a median duration not reached compared with 17 
months in patients without maintenance (p  0.001).27
In contrast to maintenance after salvage treatment in 
relapsed patients, rituximab maintenance after primary treat-
ment cannot be considered standard yet. A benefit remains to be 
proven in randomized trials. However, results of a phase II non-
randomized trial including NHL patients with mainly follicular 
histology are promising. Here, rituximab maintenance therapy 
after rituximab single-agent first-line therapy improved PFS 
compared with previous trials that had tested rituximab single-
agent activity without subsequent maintenance therapy.28
Due to its high incidence, most patients included in 
clinical trials for indolent lymphoma are of FL subtype. 
Therefore, results of trials mainly represent efficacy of 
treatment protocols in FL. However, subgroup analyses and 
studies evaluating patients with MCL, chronic lymphocytic 
leukemia (CLL) or nodular lymphocyte-predominant 
Hodgkin lymphoma (NLPHL) revealed an improved outcome 
in these entities by the implementation of rituximab.29–32 In 
CLL, the combination of fludarabine, cyclophosphamide 
and rituximab (FCR) has become standard of care. In the 
ongoing randomized CLL10 trial conducted by the German 
CLL Study Group (DCLLSG), this standard is being 
compared with BR, which had been shown to have promising 
activity in previous non-randomized trials.
In summary, rituximab has become an indispensable 
part of the treatment for indolent NHL. This holds true for 
first-line as well as for salvage and maintenance therapy 
(Table 2).
Clinical trials with rituximab  
in aggressive NHL
Lymphoma subtypes such as DLBCL, anaplastic large cell 
lymphoma (ALCL) and Burkitt lymphoma belong to the 
group of aggressive NHL. Among those, DLBCL is most fre-
quently diagnosed, with an incidence of about 3 to 4/100,000 
persons/year.33 Since most DLBCL cells express CD20, they 
are a promising target for rituximab.
After phase II trials had shown safety and activity of 
rituximab in combination with conventional chemotherapy, 
several groups conducted controlled randomized trials 
directly comparing R-chemotherapy and chemotherapy 
alone in DLBCL patients.34 In these trials patients receiving 
R-chemotherapy had a significantly superior outcome.
In 2006 Pfreundschuh and colleagues published results 
from a trial including 824 patients aged 18 to 60 with good 
prognosis DLCBL. Patients were randomly assigned to 
either 6 cycles of CHOP-like chemotherapy supplemented 
by rituximab or 6 cycles of CHOP-like chemotherapy alone. 
Bulky and extranodal sites involved were irradiated. Addition 
Table 1 impact of rituximab on the outcome of indolent lymphoma in different indications
   Regimens compared  Improved outcome by  
administration of rituximab?
References 
Conventional first-line therapy Conventional chemotherapy 
vs 
conventional chemotherapy  
supplemented by rituximab
yes 20,21,22
r-maintenance after conventional  
first-line therapy
results of randomized trials are  
pending
Not yet proven in randomized  
trials
27
Conventional second-line therapy Conventional chemotherapy 
vs 
conventional chemotherapy  
supplemented by rituximab
yes 25,46
r-maintenance after conventional  
second-line therapy
rituximab maintenance 
vs 
observation
yes 25,26
High-dose chemotherapy as  
second-line therapy
Salvage regimen without rituximab 
vs 
rituximab-containing salvage regimen
yes 47
r-maintenance after high-dose  
chemotherapy as second-line  
therapy
results of randomized trials are not 
available 
Not yet proven in randomized  
trials 
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of rituximab significantly improved the results. Three-year 
EFS was 59% in patients who received chemotherapy alone 
but 79% in patients who also received rituximab (p = 0.0001). 
Patients receiving rituximab-containing treatment also had 
a superior OS, 93% being alive after 3 years compared with 
84% in the chemotherapy-alone group (p = 0.0001).35
The Groupe d´Etude des Lymphomes de l´Adulte 
(GELA) randomly assigned 399 DLBCL patients aged 
60 to 80 to either receive 8 cycles of CHOP or 8 cycles of 
R-CHOP. Response rate was significantly higher in patients 
receiving rituximab-containing treatment, 76% of them 
achieving CR or CRu (CR unconfirmed). In contrast, only 
63% of patients in the CHOP alone arm achieved CR/CRu 
(p = 0.005). With a median follow-up of 2 years, EFS and 
OS were also significantly improved in the R-CHOP arm, 
with 70% of the R-CHOP-treated patients alive compared 
with 57% of patients in the CHOP-alone arm (p  0.001 and 
p = 0.007, respectively).36
In elderly patients with aggressive lymphoma, superior-
ity of CHOP-14 in comparison with CHOP-21 had been 
shown in a trial by the German High-Grade Non-Hodgkin’s 
Lymphoma Study Group (DSHNHL).37 A follow-up trial 
in patients over 60 years diagnosed with aggressive CD20-
positive B cell NHL compared 6 or 8 cycles of CHOP-14 
with or without rituximab. Patients treated with 6 cycles of 
R-CHOP-14 had a better outcome than patients treated with 
8 cycles of R-CHOP-14, 6 cycles of CHOP-14 or 8 cycles of 
CHOP-14, respectively. Three-year EFS was 66.5% in the 
group receiving 6 cycles of R-CHOP-14 arm compared with 
63.1%, 47.2% and 53.0% in the groups receiving 8 cycles of 
R-CHOP-14, 6 cycles of CHOP-14 and 8 cycles of CHOP-14, 
respectively. Three-year OS was also best in patients treated 
with 6 cycles of R-CHOP-14. Based on the data of this trial, 
6 cycles of R-CHOP-14 should be the preferred treatment 
in elderly patients with aggressive CD20-positive B cell 
NHL. Administration of R-chemotherapy beyond 6 cycles 
does not further improve patient outcome.38 A trial directly 
comparing R-CHOP14 and R-CHOP21 is currently being 
conducted by the GELA.
The value of rituximab maintenance in DLBCL is not 
fully defined yet. Results from a randomized trial includ-
ing 415 patients that were published by Habermann and 
colleagues in 2006 indicated a beneficial effect for rituximab 
maintenance in those patients who were treated with a 
first-line regimen not containing rituximab but not for those 
who already received rituximab-containing primary treat-
ment. In this study, rituximab maintenance was administered 
4 times at 6-month intervals.39
In an ongoing trial rituximab maintenance every 8 weeks 
for a total of 2 years is being evaluated in patients who 
previously had received a rituximab-containing induction 
regimen. The trial has not yet finished recruitment and results 
are pending.
In relapsed CD20-positive aggressive B cell NHL, 
addition of rituximab to salvage chemotherapy could also 
be shown to improve response rates and outcome. In a ran-
domized trial, 239 patients receiving salvage chemotherapy 
alone or supplemented with rituximab prior to high-dose 
chemotherapy and autologous stem-cell transplantation were 
included. Response rate was significantly better in the group 
receiving the rituximab-containing induction regimen, 75% 
of patients responding compared to 54% in the chemotherapy-
alone group (p = 0.01). With a median follow-up of 2 years, 
failure-free survival and PFS were longer in patients receiv-
ing rituximab (50% and 52% in the R-chemotherapy group vs 
24% and 31% in the chemotherapy-alone group, p  0.001 
and p  0.002, respectively). In Cox regression analysis, OS 
could also be shown to be superior in patients treated with 
the rituximab-containing scheme.40
In conclusion, rituximab has become an essential part in 
first-line as well as in salvage treatment of CD20-positive 
aggressive NHL. The value of rituximab in maintenance 
therapy cannot yet be fully defined (Table 2).
Safety, tolerability and quality of life
Generally, administration of  rituximab is safe and well 
tolerated. In most patients treatment can be conducted in an 
outpatient setting and no hospitalization is required. Most 
infusion-related reactions occur during the first administra-
tion. Reactions such as fever, urticaria, hypotension and 
bronchospasm due to cytokine release are the adverse events 
most commonly observed. Since these reactions can become 
fatal, an adequate premedication should be applied and 
reanimation equipment should be within reach. After the first 
infusion the risk of cytokine release decreases markedly.41 
Interstitial pneumonitis is a rare but potentially fatal adverse 
effect associated with rituximab.42,43 Awareness of this side 
effect is important since early treatment with glucocorticoids, 
mostly supplemented by antibiotics, leads to a full recovery 
in many patients.
The patient’s quality of life during treatment with ritux-
imab does not seem to be impaired, which is understandble 
because rituximab does not cause additional toxicity when 
used in combination with conventional chemotherapy, 
with the exception of a higher rate of leukocytopenia.44 To 
evaluate the quality of life in patients receiving rituximab OncoTargets and Therapy 2009:2 195
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maintenance, Witzens-Harig and colleagues conducted 
a prospective randomized trial. Patients with different 
subtypes of CD20-positive NHL were randomly assigned 
to either rituximab maintenance every 3 months for a total 
of 2 years or observation. Patients were handed out a set of 
questionnaires to complete. Several dimensions defining 
quality of life such as mobility, self-care, daily activities, 
pain and anxiety could be recorded on the questionnaires. 
With a total of 91 patients eligible for evaluation, no sig-
nificant differences between groups could be detected, 
indicating that rituximab maintenance does not affect the 
quality of life.45
Conclusions
In the past decade rituximab has become an essential part 
of the treatment of CD20-positive lymphoma. Addition of 
rituximab to conventional chemotherapy has significantly 
improved patient outcome, which holds true for first-line 
as well as salvage therapy. The value of rituximab in main-
tenance therapy is still under investigation and not fully 
defined yet. Since application of rituximab is commonly 
well tolerated and side effects are mostly mild, quality of 
life does not seem to be impaired in patients receiving the 
antibody. Thus, in the future the use of rituximab or possible 
follow-up products will probably be expanded to even more 
indications than at present. Various trials not only in the 
field of lymphatic malignancies but also in patients with 
autoimmune disorders such as rheumatoid arthritis, idiopathic 
thrombocytopenic purpura, systemic lupus erythematosus 
and others are currently ongoing to generate data that 
will help to define new indications for the use anti-CD20 
antibodies.
Disclosures
The authors declare no conflicts of interest.
References
  1.  Chan JK. The new World Health Organization classification of  lymphomas: 
the past, the present and the future. Hematol Oncol. 2001;19(4):129–150.
  2.  Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard 
regimen (CHOP) with three intensive chemotherapy regimens for 
advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14): 
1002–1006.
  3.  Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: 
prognostic factors for response and survival. J Clin Oncol. 1986;4(10): 
1470–1480.
  4.  Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch 
and wait policy versus immediate systemic treatment for asymptomatic 
advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. 
Lancet. 16 2003;362(9383):516–522.
  5.  Horning SJ. Natural history of and therapy for the indolent non-
Hodgkin’s lymphomas. Semin Oncol. 1993;20(5 Suppl 5):75–88.
  6.  Armitage JO, Weisenburger DD. New approach to classifying non-
Hodgkin’s lymphomas: clinical features of the major histologic sub-
types. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 
1998;16(8):2780–2795.
  7.  Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization 
of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4): 
1678–1685.
  8.  Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo 
by a chimeric mouse human monoclonal antibody to CD20. Blood. 
1994;83(2):435–445.
  9.  Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf  I. Mechanism 
of cytotoxicity induced by chimeric mouse human monoclonal antibody 
IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 
2000;204(1):55–63.
10.  Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. 
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a 
B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer 
Biother Radiopharm. 1997;12(3):177–186.
11.  Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 
(anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987; 
69(2):584–591.
12.  Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results 
of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s 
lymphoma. J Clin Oncol. 1997;15(10):3266–3274.
Table 2 impact of rituximab on the outcome of aggressive lymphoma in different indications
   Regimens compared  Improved outcome by  
administration of rituximab?
References 
Conventional first-line therapy Conventional chemotherapy 
vs 
conventional chemotherapy supplemented  
by rituximab
Yes 34,35
r-maintenance after conventional  
first-line therapy
rituximab maintenance 
vs 
observation
Variable; benefit depending on 
therapy prior to r-maintenance
38
High-dose chemotherapy as  
second-line therapy
Salvage regimen without rituximab 
vs 
rituximab-containing salvage regimen
Yes 39
r-maintenance after high-dose  
chemotherapy as second-line therapy 
rituximab maintenance 
vs 
observation
Not yet clear; trial is currently 
recruiting 
Clinical trials. 
gov Identifier:  
NCT00078949OncoTargets and Therapy 2009:2 196
Eichenauer et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
13.  Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 
(Rituximab) anti-CD20 monoclonal antibody therapy in patients with 
relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6): 
2188–2195.
14.  McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric 
anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: 
half of patients respond to a four-dose treatment program. J Clin Oncol. 
1998;16(8):2825–2833.
15.  Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum 
Rituximab (IDEC-C2B8) concentration and anti-tumor response in 
the treatment of recurrent low-grade or follicular non-Hodgkin’s lym-
phoma. Ann Oncol. 1998;9(9):995–1001.
16.  Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of 
ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients 
with relapsed or refractory B-cell chronic lymphocytic leukemia: a 
phase 1–2 study. Blood. 2008;111(3):1094–1100.
17.  Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-
function relationships of veltuzumab (hA20), a humanized anti-CD20 
monoclonal antibody. Blood. 2009;113(5):1062–1070.
18.  Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of 
ofatumumab, a novel fully human anti-CD20 monoclonal antibody in 
relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. 
Blood. 2008;111(12):5486–5495.
19.  Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients 
with low-grade B-cell lymphoma with the combination of chimeric anti-
CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 
1999;17(1):268–276.
20.  Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with 
rituximab added to the combination of cyclophosphamide, doxorubicin, 
vincristine, and prednisone (CHOP) significantly improves the out-
come for patients with advanced-stage follicular lymphoma compared 
with therapy with CHOP alone: results of a prospective randomized 
study of the German Low-Grade Lymphoma Study Group. Blood. 
2005;106(12):3725–3732.
21.  Salles G, Mounier N, de Guibert S, et al. Rituximab combined 
with chemotherapy and interferon in follicular lymphoma patients: 
results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13): 
4824–4831.
22.  Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP 
compared with cyclophosphamide, vincristine, and prednisone alone 
in patients with previously untreated advanced follicular lymphoma. 
J Clin Oncol. 2008;26(28):4579–4586.
23.  Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab 
versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. 
Cochrane Database Syst Rev. 2007(4):CD003805.
24.  Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus ritux-
imab is effective and has a favorable toxicity profile in the treatment of 
mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005; 
23(15):3383–3389.
25.  Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus 
Rituximab versus CHOP plus Rituximab in the first-line treatment of   
patients with indolent and mantle cell lymphomas - first interim results 
of a randomized phase III study of the StiL (Study Group Indolent 
Lymphomas, Germany). Blood (ASH Annual Meeting abstracts). 2007; 
110(11):Abstract 385.
26.  van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance 
improves clinical outcome of relapsed/resistant follicular non-Hodgkin 
lymphoma in patients both with and without rituximab during induction: 
results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 
108(10):3295–3301.
27.  Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy 
with rituximab leads to a significant prolongation of response duration 
after salvage therapy with a combination of rituximab, fludarabine, 
cyclophosphamide, and mitoxantrone (R-FCM) in patients with recur-
ring and refractory follicular and mantle cell lymphomas: Results of a 
prospective randomized study of the German Low Grade Lymphoma 
Study Group (GLSG). Blood. 2006;108(13):4003–4008.
28.  Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line 
and maintenance therapy for patients with indolent non-hodgkin’s 
lymphoma. J Clin Oncol. 2002;20(20):4261–4267.
29.  Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with 
rituximab and cyclophosphamide, doxorubicin, vincristine, and pred-
nisone significantly improves response and time to treatment failure, 
but not long-term outcome in patients with previously untreated 
mantle cell lymphoma: results of a prospective randomized trial of the 
German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 
2005;23(9):1984–1992.
30.  Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined 
immunochemotherapy using rituximab and fludarabine in patients with 
chronic lymphocytic leukemia. Blood. 2002;100(9):3115–3120.
31.  Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ 
Hodgkin lymphoma with the monoclonal antibody rituximab is effective 
and well tolerated: results of a phase 2 trial of the German Hodgkin 
Lymphoma Study Group. Blood. 2003;101(2):420–424.
32.  Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed 
lymphocyte-predominant Hodgkin lymphoma: long-term results of a 
phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). 
Blood. 2008;111(1):109–111.
33.  Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin’s lymphoma: 
ESMO clinical recommendations for diagnosis, treatment and follow-
up. Ann Oncol. 2008;19 Suppl 2:ii67–ii69.
34.  Vose JM, Link BK, Grossbard ML, et al. Phase II study of  rituximab 
in combination with chop chemotherapy in patients with previously 
untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001; 
19(2):389–397.
35.  Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like 
chemotherapy plus rituximab versus CHOP-like chemotherapy alone in 
young patients with good-prognosis diffuse large-B-cell lymphoma: a 
randomised controlled trial by the MabThera International Trial (MInT) 
Group. Lancet Oncol. 2006;7(5):379–391.
36.  Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus ritux-
imab compared with CHOP alone in elderly patients with diffuse 
large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
37.  Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly 
CHOP chemotherapy with or without etoposide for the treatment of 
elderly patients with aggressive lymphomas: results of the NHL-B2 
trial of the DSHNHL. Blood. 2004;104(3):634–641.
38.  Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles 
of bi-weekly CHOP-14 with or without rituximab in elderly patients 
with aggressive CD20+ B-cell lymphomas: a randomised controlled 
trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–116.
39.  Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP 
versus CHOP alone or with maintenance rituximab in older patients 
with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19): 
3121–3127.
40.  Vellenga E, van Putten WL, van ‘t Veer MB, et al. Rituximab improves 
the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/
progressive aggressive CD20+ NHL: a prospective randomized HOVON 
trial. Blood. 2008;111(2):537–543.
41.  Kimby E. Tolerability and safety of rituximab (MabThera). Cancer 
Treat Rev. 2005;31(6):456–473.
42.  Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung 
disease. Am J Hematol. 2007;82(10):916–919.
43.  Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J. Interstitial pneu-
monitis during rituximab-containing chemotherapy for non-Hodgkin 
lymphoma. Leuk Lymphoma. 2008;49(9):1778–1783.
44.  Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with 
rituximab and overall survival in patients with indolent or mantle cell 
lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 
2007;99(9):706–714.
45.  Witzens-Harig M, Reiz M, Heiss C, et al. Quality of life during main-
tenance therapy with the anti-CD20 antibody rituximab in patients with 
B cell non-Hodgkin’s lymphoma: results of a prospective randomized 
controlled trial. Ann Hematol. 2008.OncoTargets and Therapy 2009:2
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open 
access journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the 
management of cancer patients. The journal also focuses on the impact 
of management programs and new therapeutic agents and protocols on 
patient perspectives such as quality of life, adherence and satisfaction. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
197
rituximab for non-Hodgkin lypmphoma Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
46.  Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab 
to a combination of fludarabine, cyclophosphamide, mitoxantrone 
(FCM) significantly increases the response rate and prolongs survival 
as compared with FCM alone in patients with relapsed and refrac-
tory follicular and mantle cell lymphomas: results of a prospective 
randomized study of the German Low-Grade Lymphoma Study Group. 
Blood. 2004;104(10):3064–3071.
47.  Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose 
therapy with autotransplant at time of relapse in patients with follicular 
lymphoma: a GELA study. J Clin Oncol. 2008;26(21):3614–3620.
48.  Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, 
et al. Results of a prospective randomised open label phase iii study 
comparing rituximab plus mitoxantrone, chlorambucile, prednisolone 
chemotherapy (R-MCP) versus MCP alone in untreated advanced 
indolent non-Hodgkin’s lymphoma (NHL) and mantle-cell-lymphoma 
(MCL). ASH Annual Meeting Abstracts. 2004;104:584.
49.  Herold M, Haas A, Srock S, et al. Rituximab added to first-line 
mitoxantrone, chlorambucil, and prednisolone chemotherapy followed 
by interferon maintenance prolongs survival in patients with advanced 
follicular lymphoma: an East German Study Group Hematology and 
Oncology Study. J Clin Oncol. 2007;25(15):1986–1992.
50.  Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, 
et al. CVP chemotherapy plus rituximab compared with CVP as first-
line treatment for advanced follicular lymphoma. Blood. 2005;105: 
1417–1423.
51.  Rivas-Vera S, Baez E, Sobrevilla-Calvo P, Baltazar S, Tripp F, Vela J, 
et al. Is first line single agent rituximab the best treatment for indolent 
non-Hodgkin’s lymphoma? Update of a multicentric study comparing 
rituximab vs CNOP vs rituximab plus CNOP. ASH Annual Meeting 
Abstracts 2005;106:2431.